{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Sequential+Therapy&page=25", "query": { "intervention": "Sequential Therapy", "page": 25 }, "page_size": 10 }, "pagination": { "page": 25, "page_size": 10, "total_count": 716, "total_pages": 72, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Sequential+Therapy&page=26&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Sequential+Therapy&page=24&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-30T14:10:44.237Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04354246", "title": "COM902 (A TIGIT Inhibitor) in Subjects With Advanced Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Cancer", "Ovarian Cancer", "Lung Cancer", "Colon Cancer", "Plasma Cell Neoplasm", "Multiple Myeloma", "HNSCC", "Microsatellite Stable Colorectal Carcinoma", "MSS-CRC" ], "interventions": [ { "name": "Dose escalation: COM902 monotherapy.", "type": "DRUG" }, { "name": "Evaluation of safety/tolerability: COM902 in combination with COM701 (both at the RDFE)", "type": "COMBINATION_PRODUCT" }, { "name": "Cohort expansion: COM902 (RDFE) monotherapy.", "type": "DRUG" }, { "name": "Cohort expansion: COM902 in combination with COM701 (both at the RDFE).", "type": "DRUG" }, { "name": "Cohort expansion: Triplet combination of COM902 + COM701 + Pembrolizumab.", "type": "COMBINATION_PRODUCT" } ], "intervention_types": [ "DRUG", "COMBINATION_PRODUCT" ], "sponsor": "Compugen Ltd", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 94, "start_date": "2020-03-31", "completion_date": "2026-04-01", "has_results": false, "last_update_posted_date": "2026-08-12", "last_synced_at": "2026-10-30T14:10:44.237Z", "location_count": 9, "location_summary": "Sarasota, Florida • Boston, Massachusetts • Grand Rapids, Michigan + 6 more", "locations": [ { "city": "Sarasota", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Grand Rapids", "state": "Michigan" }, { "city": "Columbus", "state": "Ohio" }, { "city": "Memphis", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT04354246" }, { "nct_id": "NCT01730157", "title": "Radioembolization and Ipilimumab in Treating Patients With Uveal Melanoma With Liver Metastases", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Ciliary Body and Choroid Melanoma, Medium/Large Size", "Ciliary Body and Choroid Melanoma, Small Size", "Extraocular Extension Melanoma", "Iris Melanoma", "Liver Metastases", "Metastatic Intraocular Melanoma", "Recurrent Intraocular Melanoma", "Stage IV Intraocular Melanoma" ], "interventions": [ { "name": "ipilimumab", "type": "BIOLOGICAL" }, { "name": "yttrium Y 90 glass microspheres", "type": "RADIATION" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "RADIATION", "OTHER" ], "sponsor": "Case Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 6, "start_date": "2012-12", "completion_date": "2016-02", "has_results": false, "last_update_posted_date": "2016-03-10", "last_synced_at": "2026-10-30T14:10:44.237Z", "location_count": 1, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT01730157" }, { "nct_id": "NCT05806931", "title": "Sequential TAS-OX Alternating With TAS-IRI Plus Bevacizumab for Late-Line Metastatic Colorectal Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Colon Cancer", "Rectal Cancer" ], "interventions": [ { "name": "TAS-102, oxaliplatin, irinotecan with bevacizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Rutgers, The State University of New Jersey", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 50, "start_date": "2023-05-17", "completion_date": "2027-05-01", "has_results": false, "last_update_posted_date": "2026-03-18", "last_synced_at": "2026-10-30T14:10:44.237Z", "location_count": 9, "location_summary": "Elizabeth, New Jersey • Jersey City, New Jersey • Lakewood, New Jersey + 5 more", "locations": [ { "city": "Elizabeth", "state": "New Jersey" }, { "city": "Jersey City", "state": "New Jersey" }, { "city": "Lakewood", "state": "New Jersey" }, { "city": "Livingston", "state": "New Jersey" }, { "city": "Long Branch", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT05806931" }, { "nct_id": "NCT01297764", "title": "A Study of Carfilzomib, Lenalidomide, Vorinostat, and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Vorinostat, Lenalidomide, Carfilzomib, Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hackensack Meridian Health", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 17, "start_date": "2011-04", "completion_date": "2027-06", "has_results": false, "last_update_posted_date": "2026-08-24", "last_synced_at": "2026-10-30T14:10:44.237Z", "location_count": 1, "location_summary": "Hackensack, New Jersey", "locations": [ { "city": "Hackensack", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT01297764" }, { "nct_id": "NCT00005639", "title": "Azacitidine Plus Phenylbutyrate in Treating Patients With Advanced or Metastatic Solid Tumors That Have Not Responded to Previous Treatment", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lymphoma", "Small Intestine Cancer", "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "Azacitidine Injection", "type": "DRUG" }, { "name": "sodium phenylbutyrate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 34, "start_date": "2000-03", "completion_date": "2005-07", "has_results": false, "last_update_posted_date": "2019-01-11", "last_synced_at": "2026-10-30T14:10:44.237Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00005639" }, { "nct_id": "NCT02179086", "title": "Dose-Escalated Photon IMRT or Proton Beam Radiation Therapy Versus Standard-Dose Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Glioblastoma" ], "interventions": [ { "name": "Photon Beam Radiation Therapy", "type": "RADIATION" }, { "name": "Proton Beam Radiation Therapy", "type": "RADIATION" }, { "name": "Temozolomide", "type": "DRUG" } ], "intervention_types": [ "RADIATION", "DRUG" ], "sponsor": "NRG Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 624, "start_date": "2014-12-04", "completion_date": "2030-07-07", "has_results": true, "last_update_posted_date": "2026-10-01", "last_synced_at": "2026-10-30T14:10:44.237Z", "location_count": 230, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 179 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT02179086" }, { "nct_id": "NCT04046224", "title": "Dose-Ranging Study of ST-920, an AAV2/6 Human Alpha Galactosidase A Gene Therapy in Subjects With Fabry Disease (STAAR)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Fabry Disease" ], "interventions": [ { "name": "ST-920", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Sangamo Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 36, "start_date": "2019-07-23", "completion_date": "2025-04-10", "has_results": true, "last_update_posted_date": "2026-10-27", "last_synced_at": "2026-10-30T14:10:44.237Z", "location_count": 9, "location_summary": "Irvine, California • Tampa, Florida • Atlanta, Georgia + 6 more", "locations": [ { "city": "Irvine", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Iowa City", "state": "Iowa" } ], "official_url": "https://clinicaltrials.gov/study/NCT04046224" }, { "nct_id": "NCT04179162", "title": "Bacillus Calmette-Guérin (BCG) and Gemcitabine in People With High-Grade Non-Muscle Invasive Bladder Cancer That Came Back After BCG Treatment", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Non-Muscle Invasive Bladder Cancer (NMIBC)" ], "interventions": [ { "name": "Bacillus Calmette-Guérin (BCG)", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 54, "start_date": "2019-11-22", "completion_date": "2027-11", "has_results": false, "last_update_posted_date": "2026-08-11", "last_synced_at": "2026-10-30T14:10:44.237Z", "location_count": 8, "location_summary": "Hartford, Connecticut • Basking Ridge, New Jersey • Middletown, New Jersey + 5 more", "locations": [ { "city": "Hartford", "state": "Connecticut" }, { "city": "Basking Ridge", "state": "New Jersey" }, { "city": "Middletown", "state": "New Jersey" }, { "city": "Montvale", "state": "New Jersey" }, { "city": "Commack", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04179162" }, { "nct_id": "NCT03544788", "title": "Evaluation of Cirvo™ Mobile Compression Device for Treatment of Venous Leg Ulcers", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Venous Leg Ulcer" ], "interventions": [ { "name": "Cirvo™ Therapy", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Radial Medical, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 0, "start_date": "2019-06-30", "completion_date": "2020-02-01", "has_results": false, "last_update_posted_date": "2019-09-11", "last_synced_at": "2026-10-30T14:10:44.237Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03544788" }, { "nct_id": "NCT00415285", "title": "Docetaxel Followed by Capecitabine Versus Concomitant Docetaxel/Capecitabine for Early Stage Breast Cancer", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Neoplasms" ], "interventions": [ { "name": "Docetaxel", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "Docetaxel/Capecitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Georgia Center for Oncology Research & Education", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 100, "start_date": "2006-12", "completion_date": null, "has_results": false, "last_update_posted_date": "2007-02-13", "last_synced_at": "2026-10-30T14:10:44.237Z", "location_count": 3, "location_summary": "Atlanta, Georgia", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00415285" } ] }